CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression
Nathalie Bonnefoy, Jérémy Bastid, Gilles Alberici, Armand Bensussan, Jean-François Eliaou, Nathalie Bonnefoy, Jérémy Bastid, Gilles Alberici, Armand Bensussan, Jean-François Eliaou
Abstract
We report that CD39-expressing-melanoma cells inhibited both T-cell proliferation and the generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore antitumor immunity.
Keywords: CD39, immune checkpoints, A2A receptor, adenosine, PD1.
Source: PubMed